Handling Misconduct Introduction Technical Assistance Complainant Respondents Allegations Preliminary Assessment Inquiries Investigations Institutional Decision ORI Oversight Review PHS/HHS Decision Hearings Administrative Actions Case Summaries Legal Concerns

Case Summary - Diana Layman

[[Federal Register: June 25, 2007 (Volume 72, Number 121)]
[Notices]
[Page 34690]
From the Federal Register Online via GPO Access

[wais.access.gpo.gov] [DOCID:fr25jn07-70]

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary

Findings of Scientific Misconduct

ACTION: Notice.

SUMMARY: Notice is hereby given that the Office of Research Integrity (ORI) and the Assistant Secretary for Health have taken final action in the following case:

Diana Layman, University of Oklahoma Health Sciences Center: Based on the report of an investigation conducted by the University of Oklahoma Health Sciences Center (OUHSC) and additional analysis conducted by the Office of Research Integrity during its oversight review, the U.S. Public Health Service (PHS) found that Ms. Diana Layman, Tribal Efforts Against Lead (TEAL) phlebotomist, OUHSC, engaged in scientific misconduct in research supported by National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health (NIH), grant R01 ES008755.

Specifically, Ms. Layman falsified research in the TEAL study by substituting or conspiring with another phlebotomist to substitute her blood or blood of another phlebotomist for blood samples of 10-15 child participants in the TEAL study.

Ms. Layman has entered into a Voluntary Exclusion Agreement (Agreement) in which she has voluntarily agreed,
for a period of three (3) years, beginning on May 30, 2007:

(1) To exclude herself from any contracting or subcontracting with any agency of the United States Government and from eligibility or involvement in nonprocurement programs of the United States Government as defined in HHS' implementation of OMB Guidelines to Agencies on Governmentwide Debarment and Suspension at 2 CFR part 376, et seq.; and

(2) To exclude herself from serving in any advisory capacity to PHS, including but not limited to service on any PHS advisory
committee, board, and/or peer review committee, or as a consultant.

FOR FURTHER INFORMATION CONTACT:

Director, Division of Investigative Oversight

Office of Research Integrity

1101 Wootton Parkway, Suite 750,

Rockville, MD 20852

(240) 453-8800

John Dahlberg

Acting Director

Office of Research Integrity